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Abstract 
Purpose: Talc pleurodesis (TP) is employed worldwide for the management of persistent 
pneumothorax or pleural effusion, particularly of malignant origin. However, there are very 
little  available  data  on 
18F-fluorodeoxyglucose  positron-emission  tomography/computed 
tomography (
18F FDG PET/CT) response evaluation in malignant pleural mesothelioma (MPM) 
patients treated with TP and chemotherapy. 
Methods: Patients with histologically confirmed MPM underwent TP and FDG PET/CT staging 
and restaging after 3-4 courses of chemotherapy. All patients fasted and received a dose of 
5.18 MBq 
18F-FDG per kilogram of body weight. Whole-body emission scans were acquired 
with and without Ordered Subset Expectation Maximization (OSEM) iterative reconstruction 
algorithm.  
Results: From January 2004 to March 2010, 8 patients with biopsy confirmed MPM (7 epithelial, 
1 biphasic), with a median age of 65 years (range: 54-77), were evaluated. Median follow-up 
was 31 months (range: 4-44). After TP treatment, there was a mean interval of 14 days (range: 
9-22) and 125 days (range: 76-162) between FDG PET/CT staging and restaging. According to 
modified RECIST and EORTC criteria, there was a concordance between the radiologic and 
metabolic SUVmean and SUVmax responses in 6 (75%) and 3 (37.5%) patients, respectively.  
Conclusion:  TP  produces  an  increased  FDG  PET  uptake  which  may  interfere  with  the 
post-chemotherapy disease evaluation. In our case series, the metabolic response measured 
by SUVmean seems to be in better agreement with the radiologic response compared to the 
SUVmax. 
Key words: 18F-FDG PET-CT scan, fluorodeoxyglucose, SUV, talc pleurodesis, malignant pleural 
mesothelioma. 
Introduction 
Talc  pleurodesis  (TP)  is  a  procedure  first  de-
scribed by Bethune [1] in 1935 as a means to anchor 
the lung during lobectomy [2]. Ever since then, TP has 
been employed worldwide in the management of re-
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current  pneumothorax  and  malignant  pleural  effu-
sion, with a success rate in excess of 90% [3-5]. TP is 
performed by instillation of sterile talc into the pleural 
cavity (chemical pleurodesis), with chemical irritation 
leading to pleuritis, and ultimately to pleural fibrosis. 
Computed  tomography  (CT)  and  18F-fluorodeoxy- 
glucose  (FDG)  positron-emission  tomography  (PET) 
are  important  imaging  techniques  for  the  detection 
and staging of cancers that, used together, may pro-
vide a more accurate tumor staging tool [6]. However, 
TP treatment has been reported to increase FDG up-
take  in  thickened  pleura,  making  it  difficult  to  dis-
tinguish between benign inflammatory processes and 
malignancies, with the potential for false positive re-
sults [7-16]. 
Malignant  pleural  mesothelioma  (MPM)  is  a 
thoracic neoplasm originating from the pleural lining, 
where an increased FDG uptake has been observed 
[17], and several studies have reported on the use of 
PET to monitor chemotherapeutic response [18-21]. In 
this  setting,  the  concomitant  presence  of  a  disease 
such as MPM, and the application of a procedure like 
TP, may produce an increase in SUV that underesti-
mates the tumor response to chemotherapy. In clinical 
practice,  the  distinction  of  responding  patients  by 
those with stable or progressive disease has a prog-
nostic  implications  and  this  is  confirmed  by  some 
reports [22, 23]. The distinction of these two categories 
of disease may allow to recognize patients with better 
prognosis which may benefit by trimodality therapy 
by  those  with  a  resistant  disease  where  it  may  be 
suggested a conservative approach. 
The  aim  of  this  retrospective  MPM  case  series 
was to analyze TP-induced pleural changes by FDG 
PET/CT and to verify the concordance between met-
abolic and radiologic response after chemotherapy.  
Subjects and Methods 
Clinical data 
Inclusion  criteria  was  biopsy  confirmed  MPM 
performed  during  TP,  followed  by  FDG  PET/CT 
staging. All patients subsequently underwent three or 
four courses of Pemetrexed based chemotherapy be-
fore FDG PET/CT restaging. Written informed rou-
tinary consent was obtained from each patient before 
each examination, as standard quality of our institu-
tion require. 
FDG PET/CT evaluation 
All data were acquired on a combined PET/CT 
in-line system (Biograph Sensation 16, Siemens). Pa-
tients were instructed to fast for at least 6 h prior to 
scanning, which started 50-60 min after injection of 
5.18 MBq FDG per kilogram body weight. The glucose 
level was checked before radiotracer injection and it 
always was lower than 160 mg/dL. All patients re-
ceived a non-enhanced CT scan with 80mA, 120 kV 
parameters. Scans were acquired in the head and neck 
area, the thorax and the lower abdomen during shal-
low  breathing,  and  the  upper  abdomen  during 
non-forced expiration. Immediately after CT, the PET 
scan  was  performed  using  an  acquisition  time  of  3 
min  per  bed  position.  The  patient  remained  in  the 
same supine position on the PET/CT table through-
out the procedure, and acquisition times ranged from 
18 to 24 min. CT data were used for attenuation cor-
rection,  and  PET  images  were  reconstructed  by 
standard  2D-iterative  algorithm  (ordered  subset  ex-
pectation maximization). Images were derived from 
an isocontour Volume Of Interest (VOI) drawn over 
the  corresponding  hemithorax  region  using  a  com-
mercially available workstation (Siemens Esoft 2004). 
VOI margins were checked to cover the whole area of 
interest in all three planes. The kidneys and the myo-
cardium were spared from analysis by tracing a se-
cond VOI positioned over the heart or kidneys. The 
values  from  the  second  VOI  were  then  subtracted 
from the first VOI. The minimal SUV within the first 
VOI was set to a level of 2.5 to eliminate any physio-
logical liver uptake, that may have influenced MPM 
measurements.  An  example  of  PET/CT  scan  with 
recognized VOI is represented in Figure 1. 
All patients were radiologically staged according 
to  Brigham  and  Women’s  Hospital’s  revised  MPM 
surgical  staging  system  which  considers  tumor  his-
tology, resectability and nodal status [24]. Pleural bi-
opsies obtained during TP procedures were analyzed 
to determine the histologic MPM subtypes [25]. 
Image and response evaluations 
CT scans were assessed by a thoracic radiologist, 
experienced in MPM  measurement and unaware of 
patient outcome; radiologic response to chemothera-
py  was  assessed  using  the  modified  MPM  RECIST 
criteria [26].  
Qualitative and semiquantitative evaluations of 
PET/CT images were performed by drawing a VOI 
around the pleural thickness; SUVmax and SUVmean 
depended  on  the  initial  dose  administered  and  the 
body  mass  index.  Criteria  for  therapeutic  response 
assessment were according to the European Organi-
zation for Research and Treatment of Cancer (EORTC) 
that defined guidelines for the use of PET using FDG. 
These guidelines stated a 25% reduction in the max-
imum standardized uptake value (SUVmax) as thresh-
old for definition of partial response [27].  Journal of Cancer 2012, 3 
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Figure 1. PET/CT scan with recognisement of VOI. 
 
 
 
Statistical analysis 
Frequency tables were prepared for all categori-
cal  variables.  Continuous  variables  were  presented 
using the median and range. All analyses were carried 
out by SAS statistical software for Windows Version 
9.1 (SAS Institute Inc., Cary, NC, USA).  
Results 
Eight  patients  were  included  in  our  study,  6 
(75%) males and 2 (25%) females, with a median age 
of 65 years (range: 54-77). Histologic examination re-
vealed an epitheliod subtype in 7 (88%) cases and a 
mixed subtype in 1 (12%), 5 (63%) of which were lo-
cated on the left side and 3 (37%) on the right. Overall, 
7 (88%) stage I and 1 (12%) stage II diseases were re-
ported.  All  patients  underwent  Pemetrexed-based 
chemotherapy  (3  patients  in  combination  with  Car-
boplatin,  4  with  Cisplatin,  and  1  with  Pemetrexed 
only) with a median of 3.5 courses (range: 3-4) before 
restaging.  Patient  characteristics  are  summarized  in 
Table 1.  
After TP treatment, there was a mean interval of 
14  days  (range:  9-22)  and  125  days  (range:  76-162) 
between FDG PET/CT staging and restaging, respec-
tively, and, on average, 26 days (range: 6-46) between 
the last course of chemotherapy and the FDG PET/CT 
restaging.  
SUV mean and SUV max before and after treat-
ment is summarized in the table 2. 
We  compared  radiological  and  metabolic  re-
sponse,  as  showed  in  the  table  3.  The  concordance 
between  two  kinds  of  responses  was  respectively 
37.5% (3 out of 8 patients) and 75% (6 out of 8 pa-
tients). 
Comparing  radiologic  and  metabolic  response, 
expressed as SUVmax and SUVmean (see Table 2 and 
Table 3), the concordance was 37.5% (3 out of 8 pa-
tients) and 75% (6 out of 8 patients), respectively. 
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Table 1 Patient Features. 
Features  No. of patients (%) 
(N = 8) 
Gender   
Male  6 (75) 
Female    2 (25) 
Median age  65 (Range: 54-77) 
Stage   
I  7 (88) 
II  1 (12) 
Histology   
Epithelioid  7 (88) 
Mixed  1 (12) 
Localization   
Left  5 (63) 
Right  3 (37) 
Median cycles of chemotherapy  3.5 (Range: 3-4) 
Type of chemotherapy   
Carboplatin with Pemetrexed  3 (38) 
Cisplatin with Pemetrexed  4 (50) 
Pemetrexed only  1 (12) 
 
Table 2. Summary of SUV mean and SUV max before and 
after treatment. 
Pt 
No. 
Pre treatment  
SUVmax  
Pre treatment  
SUVmean  
Post treatment 
SUVmax 
Post treatment 
SUVmean 
1  4,6  2,78  5,3  3,15 
2  5,14  2,97  7.07  2,45 
3  3,21  2,28  4,2  2,29 
4  3,8  1,91  2,4  2,1 
5  3,2  2,3  0  2,23 
6  3,8  2,8  5.38  2,48 
7  4,69  2,61  5.36  2,23 
8  2,97  3,36  4,88  2,3 
 
Table 3. Radiological and metabolic evaluation. 
Patient No.  Radiologic response  Metabolic response 
    SUVmax  SUVmean 
1  SD  SD  SD 
2  SD  PD  SD 
3  SD  PD  SD 
4  PR  PR  SD 
5  SD  CR  SD 
6  SD  PD  SD 
7  SD  SD  SD 
8  SD  PD  PR 
CR = complete response; PR = partial response; SD = stable disease; 
PD = progression disease. 
Discussion 
Talc  pleurodesis  is  used  to  treat  patients  with 
persistent  pleural  effusions  or  pneumothorax  not 
amenable to other therapies [1-5]. Pathologic studies 
have shown that granulomatous inflammation occurs 
in the visceral and parietal pleural immediately after 
TP,  resulting  in  pleural  inflammation.  For  several 
years, this has been presumed to be the cause of in-
creased FDG activity, leading to the difficulty in dis-
tinguishing between benign and malignant disease [7, 
8, 10]. MPM is a malignancy arising from the pleural 
sierosa with an FDG-avidity [17], and this character-
istic has been proposed to evaluate chemotherapeutic 
response [18-21]. Pleural inflammation, induced by TP 
and MPM, produces pleural thickening or nodularity 
detected by radiologic examination, and the resulting 
increase  in  SUV  uptake  leads  to  biases  in  the 
post-chemotherapy  evaluation.  Increased  FDG  up-
take, with an associated increase in the thickness of 
non calcified pleural lesions, or new FDG-avid pleural 
lesions without associated calcification, are suspicious 
for  malignancy,  whereas  FDG  uptake  in  calcified 
pleural lesions suggests benign TP-induced changes. 
Currently,  little  clinical  data  is  available  on 
which is the best metabolic index to reduce chemo-
therapy evaluation bias in MPM patients previously 
treated with TP. In our experience, considering that 
morphologic changes shown by CT-scan predict re-
sponse  to  chemotherapy  [26],  we  observed  that  the 
metabolic response measured by SUVmean seems to 
be in better agreement with the radiologic evaluation 
compared to the SUVmax, but without reaching sta-
tistical significance. This may probably be due to the 
relatively  small  number  of  cases  in  our  study,  and 
therefore  a  larger  prospective  study  is  required  to 
confirm our hypothesis. 
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